Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.64)
# 826
Out of 5,041 analysts
85
Total ratings
56.34%
Success rate
25.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $10.50 | +14.29% | 5 | Sep 15, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $510 → $475 | $421.39 | +12.72% | 19 | Sep 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $463.43 | +11.14% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $4.36 | -54.13% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $67.61 | +46.43% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $28.06 | +60.37% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.20 | +66.67% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $3.72 | +34.41% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $38.93 | -10.10% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $421.50 | -14.59% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.19 | +68.35% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $14.79 | +123.12% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $53.77 | -29.33% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $33.53 | +138.59% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $12.44 | +44.69% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.95 | +532.91% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.86 | +497.27% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $29.22 | -17.86% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $14.25 | +110.53% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.36 | +129.36% | 1 | Feb 5, 2020 |
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $10.50
Upside: +14.29%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510 → $475
Current: $421.39
Upside: +12.72%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $463.43
Upside: +11.14%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $4.36
Upside: -54.13%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $67.61
Upside: +46.43%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $28.06
Upside: +60.37%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.20
Upside: +66.67%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $3.72
Upside: +34.41%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $38.93
Upside: -10.10%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $421.50
Upside: -14.59%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.19
Upside: +68.35%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $14.79
Upside: +123.12%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $53.77
Upside: -29.33%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $33.53
Upside: +138.59%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $12.44
Upside: +44.69%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.95
Upside: +532.91%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.86
Upside: +497.27%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $29.22
Upside: -17.86%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $14.25
Upside: +110.53%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.36
Upside: +129.36%